- Home
- NAK vs PHAR Comparison
NAK vs PHAR Comparison
Compare NAK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAK
- PHAR
- Stock Information
- Founded
- NAK 1983
- PHAR 1988
- Country
- NAK Canada
- PHAR Netherlands
- Employees
- NAK N/A
- PHAR N/A
- Industry
- NAK Precious Metals
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NAK Basic Materials
- PHAR Health Care
- Exchange
- NAK Nasdaq
- PHAR Nasdaq
- Market Cap
- NAK 1.1B
- PHAR 951.7M
- IPO Year
- NAK 2002
- PHAR N/A
- Fundamental
- Price
- NAK $2.03
- PHAR $13.75
- Analyst Decision
- NAK Strong Buy
- PHAR Strong Buy
- Analyst Count
- NAK 2
- PHAR 3
- Target Price
- NAK $2.50
- PHAR $30.00
- AVG Volume (30 Days)
- NAK 29.8M
- PHAR 10.7K
- Earning Date
- NAK 11-14-2025
- PHAR 11-06-2025
- Dividend Yield
- NAK N/A
- PHAR N/A
- EPS Growth
- NAK N/A
- PHAR N/A
- EPS
- NAK N/A
- PHAR N/A
- Revenue
- NAK N/A
- PHAR $339,836,000.00
- Revenue This Year
- NAK N/A
- PHAR $17.70
- Revenue Next Year
- NAK N/A
- PHAR $12.25
- P/E Ratio
- NAK N/A
- PHAR N/A
- Revenue Growth
- NAK N/A
- PHAR 22.44
- 52 Week Low
- NAK $0.39
- PHAR $7.31
- 52 Week High
- NAK $2.98
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- NAK 58.64
- PHAR 46.62
- Support Level
- NAK $1.74
- PHAR $13.08
- Resistance Level
- NAK $2.23
- PHAR $14.81
- Average True Range (ATR)
- NAK 0.34
- PHAR 0.55
- MACD
- NAK -0.05
- PHAR -0.13
- Stochastic Oscillator
- NAK 23.60
- PHAR 29.12
About NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.